Monte Rosa Therapeutics presented preclinical data at AACR 2026 demonstrating that its molecular glue degrader MRT-55811 effectively targets CCNE1-amplified solid tumors, including ovarian, breast, and gastric cancers. MRT-55811 showed deep tumor regression and superior selectivity compared to CDK2 inhibitors, potentially reducing side effects. The drug works by selectively degrading the cyclin E1/CDK2 complex, a key driver in cancer cell proliferation. Monte Rosa plans to submit an IND later this year to advance clinical development.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) surged past the $1,894.89 resistance level, accelerating its recovery toward the $1,940–$1,950 zone after days of consolidation. This breakout was supported by lower-than-expected U.S. inflation data, which boosted risk appetite and bu...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
Ethereum's price rose about 11% over the past week to around $1,920, outperforming major cryptocurrencies like Bitcoin and Solana. This rally is fueled by $96 million inflows into U.S. spot Ether ETFs early in the week, with BlackRock's ETHA product ...
The XRP Ledger has surpassed 8 million activated accounts, marking steady growth since March 2026. However, daily active addresses have declined to a 2026 low of 25,350, indicating less frequent user engagement despite overall adoption. XRP's price f...
